uMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC
Jason Scovell
Advertisement
Articles by Jason Scovell
Surgery after neoadjuvant immune checkpoint inhibitor therapy for renal cell carcinoma is safe even in challenging surgical cases, according to Jason Scovell, MD.
Advertisement
Latest Updated Articles
Nadofaragene Firadenovec Results in uMRD-Negative Status in NMBICPublished: January 28th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
3
Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC
4
Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer
5
